NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
57894-0502-20 | 57894-0502 | Daratumumab | Darzalex | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Nov 16, 2015 | Nov 30, 2026 | In Use |
55513-0326-01 | 55513-0326 | rituximab-arrx | Riabni | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
67457-0847-44 | 67457-0847 | Trastuzumab | OGIVRI | 420.0 mg/ 20 mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Nov 29, 2019 | Apr 30, 2027 | In Use |
50242-0061-01 | 50242-0061 | Bevacizumab | Avastin | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Feb 26, 2004 | In Use | |
72606-0011-01 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 3, 2023 | In Use | |
55513-0132-01 | 55513-0132 | trastuzumab-anns | Kanjinti | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 11, 2019 | In Use | |
55513-0207-01 | 55513-0207 | Bevacizumab-awwb | MVASI | 400.0 mg/16mL, 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
00003-2291-11 | 00003-2291 | Elotuzumab | Empliciti | 300.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov 30, 2015 | In Use | |
50242-0070-86 | 50242-0070 | Obinutuzumab | Gazyva | 1000.0 mg/40mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov 4, 2013 | In Use | |
00069-0238-01 | 00069-0238 | Rituximab-pvvr | Ruxience | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 23, 2020 | In Use | |
58468-0357-03 | 58468-0357 | Alemtuzumab | Campath | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD52 | Intravenous | Nov 30, 2009 | In Use | |
75929-0787-36 | 75929-0787 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
59630-0222-30 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | Jul 5, 2018 | Dec 31, 2020 | No Longer Used | |
59630-0222-07 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | Jul 5, 2018 | Dec 31, 2020 | No Longer Used | |
59385-0041-30 | 59385-0041 | Naldemedine, naldemedine tosylate | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | Jun 14, 2019 | In Use | ||
59630-0222-90 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | Jul 5, 2018 | Dec 31, 2020 | No Longer Used | |
59385-0041-07 | 59385-0041 | Naldemedine, naldemedine tosylate | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | Jul 1, 2020 | In Use | ||
64067-0216-01 | 64067-0216 | Methoxsalen | UVADEX | 20.0 ug/mL | Chemotherapy | Photosensitizing Agent | Psoralen | Extracorporeal | Feb 25, 1999 | In Use | |
76128-0155-75 | 76128-0155 | Porfimer sodium | Photofrin | 75.0 mg/31.8mL | Chemotherapy | Photosensitizing Agent | Cytotoxin | Intravenous | Dec 27, 1995 | In Use | |
68001-0265-25 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
55390-0292-01 | 55390-0292 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Feb 1, 1997 | Jun 30, 2013 | No Longer Used | |
16729-0114-11 | 16729-0114 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Mar 3, 2015 | In Use | |
00378-3266-94 | 00378-3266 | Etoposide | Etoposide | 50.0 mg/1 | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Oral | Oct 22, 2001 | In Use | |
63323-0104-06 | 63323-0104 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Sep 9, 2022 | In Use | |
16729-0262-32 | 16729-0262 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Oct 31, 2021 | Oct 31, 2021 | No Longer Used |
Found 11465 results — Export these results